- This topic has 66 replies, 14 voices, and was last updated 8 years, 4 months ago by
.
-
Serg wrote:
Another question is possible – if we possibly have initial 7% blip of HCC risks after treatment, then, does it mean that treatment with DAAs with cirrhosis looks like some sort of “Russian roulette” game with 1 “HCC-bullet” per 13 empty chambers?
Only if we wish to be over-melodramatic Serg. Most people would call it a risk-benefit analysis and weigh up the two sides and make a decision that is appropriate for them just like they would with any other medical procedure.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
To be clear, I cited the thread not the analogy that was included in a post within it and I made no statements about “negative connotation” or that the analogy should not be used on the forum. I do stand by what I stated.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
- You must be logged in to reply to this topic.